“The prevalence of obstructive sleep apnea (OSA) in Americans is 9% and increasing…
Vagal afferent neurons are inhibited by cannabinoid type 1 (CB1) or cannabinoid type 2 (CB2) receptors in animal models of vagally-mediated behaviors…
These findings underscore the therapeutic potential of dronabinol (THC) in the treatment of OSA and implicate participation of both cannabinoid receptors in dronabinol’s apnea suppression effect.”